Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2019

View Archived Issues

NTHL1 mutations lead to tumor predisposition syndrome

Drop the MIC? At least add to it

AAAS Annual Meeting: Science is there to make universal flu vaccine; money to follow?

Afibromer shielded engineered allogeneic cells demonstrate safety and efficacy in hemophilia A model

FAK as a potential new target in triple-negative breast cancer

CMG-002 overcomes chemoresistance in preclinical models of ovarian cancer

Bayer and Evotec present the discovery of BAY-293

GPR39 agonist reduces alcohol intake in mouse model of alcohol use disorder

Melittin-nanoparticles target liver sinusoidal endothelial cells and suppress liver metastasis

Enrollment underway in phase I study of J-147

Otsuka Pharmaceutical initiates two phase III trials of centanafadine in adults with ADHD

Human parthenogenetic stem cell therapy improves experimental traumatic brain injury deficits

Novartis discloses new FOXO3 inhibitors and RAC activators

WuXi AppTec and BioLingus establish sublingual drug delivery collaboration

Merck & Co. divulges IDO1 inhibitors

Saniona reports data from second part of phase IIa study of Tesomet in Prader-Willi syndrome

FASST study of lanifibranor in diffuse cutaneous systemic sclerosis does not meet primary endpoint

Keimyung University presents HSP90 inhibitors

Takeda Pharmaceutical identifies orexin OX2 receptor agonists

FronThera US Pharmaceuticals describes PI3K inhibitors

Grant supports NovaBiotics' development of Novamycin

Phase III topline results for tanezumab in chronic low back pain

Phase III REGENERATE study of OCA in liver fibrosis due to NASH achieves primary endpoint

Topline results from Japanese confirmatory phase III study of ONO-5704 in knee osteoarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...